Introduction
============

Anticancer treatment-related mucosal damage to the oral cavity is referred to as oral mucositis, and until recently it has been underestimated and overlooked ([@b81]). Treatments of this important side effect have likely been suboptimal and based on assumptions rather than evidence. In addition, physiopathologic aspects have not been addressed. Fortunately, this important issue has received greater attention in recent years because oral mucositis not only has a dramatic impact on the patient\'s quality of life, but it also can adversely influence the administration of an optimal antineoplasic treatment. Frequently, dose reductions, treatment delays, or discontinuations are necessary to allow the oral lesions to heal. In addition, life-threatening infections and higher treatment costs are clearly related to the severity of oral mucositis. Additional days of total parenteral nutrition, use of narcotic analgesics, total hospital charges, and 100-day mortality are also linked to the severity of mucositis ([@b63]).

Important epidemiologic studies have been conducted in an attempt to isolate risk factors and a great deal of basic research has advanced our understanding of the mechanisms underlying oral mucositis. Taken together, these findings have provided the basis for the development of new target therapies. Recently there have been efforts to summarize knowledge acquired in the treatment of stomatitis. A critical review of the literature allowed a panel of experts to propose clinical practice guidelines for the prevention and treatment of this complication ([@b63]; [@b68]). This panel of experts from the Multinational Association of Supportive Care and the International Society for Oral Oncology (MASSC/ISOO) formed the Mucositis Study Section. In this paper, we will focus on anticancer-induced oral mucositis, detailing the physiopathology and the treatment of this devastating complication. We will particularly emphasize the emerging role of palifermin (recombinant human keratinocyte growth factor), the first US Food and Drug Administration (FDA)-approved target therapy for oral mucositis.

Epidemiology
============

Cancer patients consider oral mucositis to be the most difficult treatment-related toxicity to endure. The frequency of oral mucositis is about 30% to 40% in the general cancer patient population ([@b69]). However, patients receiving high-dose chemotherapy (HDC) conditioning before hematopoietic stem cell transplant (HSCT) have a 76% chance of developing mucositis ([@b60]). In addition, patients receiving radiation, especially for head-and-neck cancers, have a 30% to 60% chance of suffering from this complication. The increased incidence is not only related to drugs used but also to the number of chemotherapy cycles and the previous occurrence of mucositis ([@b60]). It is estimated that annually there are approximately 400 000 cases of therapy-induced oral mucositis ([@b60]). Risk factors can be divided into two main categories: risks related to patient status and those related to the treatment itself.

Patient-related risks
---------------------

Age has been shown to be a risk factor because children experience more frequent and debilitating mucositis, probably because of high cellular turnover. In addition, patients over 50 years of age may develop severe mucositis, perhaps because of insufficient DNA repair ([@b5]). Female patients are more likely to develop oral mucositis, for instance after 5-fluorouracil (5-FU) treatment ([@b70]). Nutritional status, type of malignancy, drug-induced xerostomia (dry mouth), pre-existing mouth damage, and periodontal status also play a role. Tobacco and alcohol consumption is probably an important risk factor, although this remains controversial ([@b18]).

In addition, there has been a recent focus on genetic predisposition for oral mucositis. Enzymatic phenotypes probably play a key role in explaining the huge variation of interindividual tolerance to anticancer treatment. For instance, [@b75] reported that in patients undergoing HDC for HSCT, a polymorphism in the 5, 10-methylenetetrahydrofolate reductase gene was associated with a differential rate of oral mucositis after treatment with methotrexate. Finally, previous episodes of oral mucositis are also an important risk factor.

Treatment-related risk
----------------------

Mucositis is the second most frequent dose-limiting factor in patients receiving chemotherapy ([@b55]). Chemotherapeutic drugs affecting DNA synthesis are particularly stomatotoxic. For instance, 5-FU administration is associated with oral mucositis in about 40% of patients ([@b58]), and grade 3 to 4 oral mucositis is observed in 10% to 15% of 5-FU recipients ([@b47]). There is an increased risk of mucositis with bolus and continuous infusions compared with prolonged and repetitive low doses of chemotherapeutic agents ([@b60]). Other cytotoxic agents are known to be very damaging to mucosa (eg, alkylating agents such as anthracyclines and taxanes and folate-based drugs such as methotrexate) ([@b66]; [@b81]). Finally, some drugs are excreted in the saliva, such as methotrexate and etoposide ([@b60]).

The dose of chemotherapy is also of great importance, as illustrated by the 85%--95% incidence of mucositis in HSCT recipients. Conditioning regimens including melphalan are associated with high rates of oral mucositis ([@b78]). In this setting, mucositis has been reported by patients as the most distressing side effect they had to cope with ([@b8]). It is interesting to note that allogeneic transplant recipients experience higher grades of mucositis compared with those receiving autologous transplants ([@b81]). In addition, there is a strong relationship between low neutrophilic count and the severity of stomatitis ([@b65]).

Radiotherapy is also associated with an increased risk of mucositis. The risk varies with dose, fractioning, and the site of radiotherapy. In head-and-neck cancer patients, the incidence of mucositis is over 50%, and this rate increases when chemotherapy is given concomitantly or in HSCT recipients when total body irradiation is administered ([@b74]; [@b63]). Accelerated fraction even increases the risk of mucositis to \>70%, at which point mucositis is often dose limiting ([@b74]). A summary of the different risk factors is presented in [Table 1](#tbl1){ref-type="table"}.

###### 

Proven and suspected risk factors for the development of mucositis

  Risk factors for the development of mucositis                                 
  ----------------------------------------------- ----------------------------- ----------------------------
  Age: Children and over 50 years old             Chemotherapy:                 Type of drug
                                                                                Dose and intensity
                                                                                Induced neutropenia
  Female sex                                      Radiotherapy:                 Fractioning
                                                                                Location
                                                                                Combined with chemotherapy
  Denutrition                                     Bone marrow transplantation   
  Tumor location (eg, oral cavity, throat)                                      
  Drug-induced xerostomia                                                       
  Pre-existing mouth damage                                                     
  Periodontal status                                                            
  Tobacco and alcohol consumption                                               
  Genetic predisposition                                                        

The severity of mucositis has a direct influence on the treatment planning with the necessity of dose reductions, delays, or even discontinuations of anticancer therapy. This condition also can favor the development of life-threatening infections, especially if the patient is neutropenic. We recently reported the case of a head-and-neck cancer patient with extensive stomatitis who developed a *Saccharomyces cerevisiae fungemia* infection during concomitant chemoradiotherapy ([@b29]).

Oral mucositis has important economic costs. In a recent economic study, patients with mucositis had significantly higher costs for nutrition/hydration support and prescription medications but not for hospitalization compared with head-and-neck cancer patients free of mucositis. This difference resulted, however, in higher total costs for patients with mucositis ([@b54]).

Finally, it should be noted that there are huge discrepancies in the way the severity of mucositis is described. Different scales exist; the most commonly used are the National Cancer Institute -- Common Toxicity Criteria and the scale developed by the World Health Organization ([@b68]). These scales are graded from 0 to 4, and they are highly reproducible and easy to use, combining evaluation of objective functions and symptomatic variables. Grades III and IV are the most debilitating states because patients are no longer able to eat or require parenteral or enteral support. Other scales have been developed, but they are essentially used for research purposes. All of these methods of evaluation have been extensively reviewed by [@b68] and [@b55]. Recently, interesting pathologic evaluations also have been described. These evaluations result in, for example, estimates of the cell viability after mouthwashes using trypan blue coloration ([@b83]), measurement of neutrophil levels in mouthwashes ([@b28]), or assessment of epithelial cell morphology, and differentiation/maturation ([@b82]). The use of these in vitro pathological tests must be encouraged because they can reduce the bias of subjective methodology.

Physiopathology
===============

Clinically, oral mucositis appears about 7 to 10 days after the start of chemotherapy. Recovery occurs between days 14 to 21 ([@b65]). However, mucositis complicating radiotherapy usually develops later, and it has a more chronic course ([@b68]). It starts at a cumulative dose of 15 Grays (Gy) and peaks at 30 Gy. Despite this difference in timing of occurrence, physiopathologic mechanisms underlying the development of oral mucositis are probably identical, and these mechanisms have recently been thoroughly explored. It has become clear now that oral mucositis is not only the direct consequence of a direct physical or chemical epithelial damage but also the result of a cascade of events involving the entire mucosa ([@b69]). Recently, Sonis and co-workers ([@b20]) proposed an interesting model that describes the different biological events occurring during mucositis. In this model, five different but interdependent phases have been identified, as described below and depicted in a flow chart in [Figure 1](#fig1){ref-type="fig"}.

![Flow chart of the different phases of mucositis development.](tcrm0202-159-f1){#fig1}

Initiation
==========

Initiation is the first phase. Immediately after exposure to radiotherapy or chemotherapy, there is DNA and non-DNA damage. This damage is observed in mucosa and submucosa, but only a small proportion of cells die quickly ([@b69]). However, this initial insult triggers a cascade of biological events. Generation of oxidative stress and reactive oxygen species is thought to be the origin of injuries to mucosal cells, tissues, and blood vessels.

Message generation
==================

Message generation is the second phase. During this period, there is an upregulation of transcription factors, such as nuclear factor-κB (NF-κB), and genes coding for proinflammatory cytokines (eg, tumor necrosis factor \[TNF-α\], and interleukins \[ILs\] IL-1, IL2, and IL-6) and adhesion molecules. In addition, enzymes such as neutral and acidic sphingomyelinases and ceramide synthase are activated. This activation results in apoptosis of submucosal endothelial cells and fibroblasts. Fibroblast destruction leads to generation of fibronectin, which is responsible for a breakdown in connective tissue and the release of metalloproteinases responsible for more apoptosis. It should be noted that at this time the mucosa still seems clinically normal.

Signaling and amplification
---------------------------

Signaling and amplification is the third phase. During this period, the release of mediators from the initial injury amplifies the destruction process through activation of positive feedback loops, eg, TNF-α activates NF-κB ([@b71]) and sphingomyelinase ([@b3]), leading to additional tissue destruction. It is interesting to note that in fractionated radiotherapy, the insult is permanent and feedback loops are constantly activated, blocking the healing process ([@b69]).

Ulceration
----------

Ulceration is the fourth phase. During this period mouth injuries become clinically evident with areas of erosion. Erosions are covered by fibrinous exudates that are also called "pseudomembrane". The exudate contains oral bacteria. This period frequently coincides with the lowest neutrophil count. Bacterial colonization of the submucosa is present and activates macrophages, leading to new positive feedback and more proinflammatory cytokine secretion. Other cytokines, such as platelet-activating factor (PAF), may play an important role at this stage. It seems that platelet aggregation may worsen oral mucositis ([@b38]). High salivary PAF levels are correlated with mucositis severity ([@b46]), and pharmacologic inhibition of platelet aggregation results in reduction of mucositis ([@b77]). Finally, angiogenesis is a late event of mucositis-induced ulcers.

Healing
-------

Healing is the last phase. During this period, because of some not yet well-characterized signals, epithelial cells directly bordering the site migrate, proliferate, and differentiate. These cells move beneath the pseudomembrane to reconstitute an intact surface. This phenomenon is frequently concomitant with the return of the white blood cell count to normal values. Cells proliferate until the thickness of the mucosa is normal. However, despite the fact that the mucosa appears to be clinically normal, the environment has been altered and does not revert to its original normal state. The patient is at risk of subsequent injury with antineoplasic treatments.

Many unanswered questions remain concerning the physiopathology of oral mucositis; for instance, the role of saliva in the pathogenesis of oral injury is unclear. Saliva plays a major role in oral homeostasis, notably through salivary immunoglobulin A ([@b21]); however, surprisingly, an attempt to increase production by pilocarpine hydrochloride in cases of decreased or absent saliva (ie, xerostomia) failed to moderate oral mucositis ([@b40]).

Prevention and treatment of oral mucositis
------------------------------------------

Many strategies exist to prevent and treat oral mucositis; most of these are not generally accepted and are frequently based on anecdotal reports or experiences. The lack of large, well-designed randomized clinical studies adds to the confusion. Recently a panel of experts reviewed the oral mucositis literature and summarized the conclusions in clinical guidelines ([@b63]; [@b68]). Fortunately, because of a growing interest in this important side effect of cancer treatment, interesting clinical studies have been reported, and new drugs have been developed and tested.

Management of oral mucositis can be artificially divided in three basic components: general oral care, prevention, and palliative cares ([@b65]).

General oral care
-----------------

General oral care is the basis of oral mucositis management, and it has a crucial role in prevention of its occurrence. The aim is to reduce some host-related risk factors for stomatitis, including lowering the impact of oral microbial flora. First a pre-treatment oral assessment of the patient should be performed. Comprehensive patient education plays a central role, and a standard oral care protocol should be applied, but there is not enough evidence to recommend one protocol over another ([@b65]). However, collective studies suggest that the use of a systematic protocol improves patient outcome ([@b63]). Some simple care should be suggested, for instance: brushing teeth twice daily using a new toothbrush at each chemotherapy cycle, daily flossing, and mouth rinsing with sterile water after each brushing or flossing. In addition, spicy food, alcoholic beverages, and alcohol-based mouthwashes should be avoided ([@b39]). Topical antimicrobial treatments have frequently been shown to be ineffective in modifying mucositis ([@b69]). For instance use of amphotericin B, tobramycin, and polymyxin B has shown efficacy in preventing oral mucositis induced by radiotherapy but not by chemotherapy ([@b17]). This paradox can be explained in part by the physiopathology of oral mucositis. These three compounds, in addition to their anti-infective activity, also affect the production of pro-inflammatory cytokines. Amphotericin B induces the expression of genes coding for TNF-α and IL-1β ([@b62]) while both tobramycin and polymyxin B attenuate the production and activity of these cytokines ([@b26]).

Prevention
----------

Prevention is the second most important factor in addressing oral mucositis.

Cryotherapy
===========

Cryotherapy consists of the use of ice chips when bolus 5-FU chemotherapy is administered. This cryotherapy induces a temporary vasoconstriction, reducing blood flow and chemotherapy delivery to oral mucosa ([@b65]). This procedure has been validated in two randomized clinical trials ([@b43]; [@b12]). The group receiving cryotherapy experienced a reduction in mucositis of approximately 50% ([@b43]). In practice, ice chips are given for 30 minutes, starting 5 minutes before the beginning of the chemotherapy. It should be noted that this procedure is neither useful for continuous infusion of 5-FU nor for methotrexate and anthracycline-containing therapies since the half-life of these drugs is too long ([@b63]). The advantages of this procedure are its simplicity, lack of toxicity, and low cost.

Low level laser therapy
=======================

Low level laser therapy (LLLT) is also an important part of the prevention strategies of mouth mucositis ([@b27]). This procedure has been shown to be effective in patients receiving HDC and HSCT ([@b6]; [@b15]). It promotes wound healing and reduces pain and inflammation ([@b63]). In addition, LLLT produces no toxicity and is nontraumatic to patients but requires expensive materials and is time consuming.

Amifostine
==========

Amifostine is a radioprotectant pro-drug that when dephosphorylated protects normal but not malignant cells against oxygen-based radicals, alkylator or organoplatinum anticancer drugs ([@b72]), and radiotherapy. It acts as a free-radical scavenger and has been shown to reduce pro-inflammatory cytokine levels ([@b69]). The protection of normal cells results in part from improved vascularity, higher alkaline phosphatase levels (required for dephosphorylation of amifostine into its active metabolite WR-1065), and higher pH of normal tissues ([@b72]). One randomized trial has shown that amifostine reduced the incidence of xerostomia, but not the severity of oral mucositis after radiotherapy for head-and-neck cancers ([@b11]). A recent randomized trial suggested that for ovarian cancer patients, the frequency of severe grade III to IV carboplatinand paclitaxel-induced mucositis was reduced with amifostine infusion ([@b41]). [@b72] also suggested that amifostine reduced the median grade of oral mucositis and the severity of mucositis, but not the requirement of parenteral nutrition or analgesic use after high-dose melphalan and HSCT for multiple myeloma. Finally, amifostine reduced the frequency of severe esophagitis after chemo-radiotherapy for non-small-cell lung cancer (NSCLC) ([@b37]). Guidelines do not recommend amifostine for prevention of oral mucositis except for NSCLC patients undergoing concomitant chemo-radiotherapy ([@b63]). One of the main issues with amifostine administration is the toxicity. Nausea, vomiting, hypotension, sneezing, flushing, somnolence, metallic taste, allergic reactions, and hypocalcemia have been frequently reported. However, subcutaneous injection could be more tolerable ([@b7]).

Chlorhexidine
=============

Chlorhexidine reduces mucosal colonization by microorganisms, but this effect has never been translated into clinical benefits for patients receiving either chemotherapy or conventional or high-dose radiotherapy ([@b65]). In a randomized trial, chlorhexidine was found to be less effective and more toxic than a placebo rinse in patients with head-and-neck tumors receiving radiotherapy ([@b24]). Chlorhexidine is not recommended in the clinical guidelines ([@b63]). In addition, chlorhexidine has several side effects including inflammation, mouth discomfort, taste alterations, and teeth staining ([@b57]).

Gelclair^®^
===========

Gelclair^®^was approved by the FDA in 2002 as a class 1 medical device. It is a bioadherent gel that works by forming a coating over mucosal lesions. Gelclair consists of polyvinylpyrrolidone, hyaluronic acid, and glycerrhetinic acid. It is thought that this molecule has anti-inflammatory properties. This preparation is well tolerated and easy to use and has been shown to be effective in reducing pain and oral discomfort in patients with mucositis ([@b32]).

Benzydamine
===========

Benzydamine is a non-steroidal anti-inflammatory drug used topically. It also has cytoprotective, anesthetic, and antimicrobial properties ([@b81]). This drug is recommended by the MASCC/ISOO panel of experts for prevention of radiotherapy-induced mucositis ([@b63]). This product is safe, but its efficacy for prevention of chemotherapy-induced mucositis is still unknown ([@b56]).

Glutamine
=========

Glutamine is a neutral amino acid rich in nitrogen that plays an important role in mucosal cellular metabolism. In cancer patients treated by chemotherapy or radiotherapy, a significant glutamine depletion is frequently observed ([@b65]). Conflicting results have been published about the effect of glutamine repletion in cancer patients. No positive effect was reported for patients receiving 5-FU chemotherapy ([@b33]; [@b51]); however, two smaller studies demonstrated a reduction in oral mucositis grade and duration for patients who did not receive 5-FU ([@b67]; [@b1]). The effect of glutamine repletion in the BMT setting is also controversial with positive ([@b2]) and negative ([@b59]) studies.

AES-14 (Saforis^TM^)
====================

AES-14 (Saforis^TM^) by Aesgen Inc., Princeton, NJ, USA, is an oral suspension delivering concentrated L-glutamine to the oral mucosa through a proprietary vehicle. This system received a fast-track approval from the FDA in January 2003 based on studies showing a reduction of mucositis severity in BMT patients and a shorter healing time after radiation ([@b20]) compared with placebo. In addition AES-14 has a very favorable toxicity profile.

Hematopoietic-growth factors
============================

It has long been observed that mucositis often resolves within days of granulocyte recovery. Some reports suggest that granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) can reduce oral mucositis by accelerating neutrophil recovery ([@b79]). However, randomized trials are controversial with positive ([@b14]; [@b35]) and negative results ([@b45]; [@b44]). There is currently no evidence supporting use of G-CSF or GM-CSF subcutaneously or in the form of mouthwash for patients with oral mucositis ([@b36]; [@b16]). In addition, these medications are very expensive.

Repifermin
==========

Repifermin is the human keratinocyte growth factor 2 (KGF-2). This substance has been studied in a phase II trial in which patients received conditioning chemotherapy before autologous HSCT. Repifermin significantly decreased the incidence of grade 2 to 4 mucositis ([@b25]).

Palifermin
==========

Palifermin is the recombinant keratinocyte growth factor 1 (rHuKGF-1). This molecule was purified from fibroblast culture fluid in 1989 as a protein of 26--28kDa ([@b64]). Cloning showed that KGF and its receptor are members of the fibroblast growth factor (FGF) family with 30%--45% homology with other proteins of the FGF family ([@b23]). It is also called FGF-7. Keratinocyte growth factor is produced by fibroblasts and microvascular endothelial cells in different organs like lungs, skin, stomach, and bladder ([@b42]). Keratinocyte growth factor receptor expression has been found in gut epithelium, hepatocytes, skin keratinocytes, alveolar type II cells, mammary epithelium, and urothelium. Keratinocyte growth factor is also a mediator of hair follicle growth and development ([@b50]). It can be considered as a mesenchymally-derived paracrine mediator of epithelial growth and development ([@b42]).

Like other members of the FGF family, KGF is a heparin-binding molecule and heparin is required for maximal KGF stimulation through its receptor ([@b31]). When bound to the receptor, KGF is internalized by endocytosis ([@b42]). Keratinocyte growth factor expression seems mediated by pro-inflammatory cytokines like TNF-α, IL-1, and IL-6 ([@b13]). Glucocorticoids appear to decrease KGF production (impairing wound healing) while estrogen and progesterone increase KGF in mammary gland and endometrium ([@b42]). Beneficial effects of KGF on mucosa seem to be broader than expected. For instance, KGF upregulates the transcription factor Nrf 2 that encodes genes playing a role in detoxifying radical oxygen species ([@b10]; [@b4]), attenuating TNF-α, and in the expression of adhesion molecules ([@b34]).

One major concern about KGF is the presence of the receptor on malignant cells from a variety of tissues ([@b50]). This finding has raised the possibility that exogenous KGF might stimulate tumor cells. Interestingly, some authors observed increased expression of the KGF/KGF receptor in more-differentiated and less-advanced tumors, and absence of expression in malignant versus benign cells or a switch to FGF receptor isoforms with low binding affinity to KGF ([@b50]). In addition, KGF has been described as stimulating matrix metalloproteinases and inducing angiogenesis, mechanisms related to tumor progression and metastatic potential. Fortunately, several reports have shown that even if KGF modestly stimulated tumor cell growth for a minority of solid tumor samples tested, it did not impair tumor sensitivity to chemotherapy ([@b50]) or radiotherapy ([@b30]).

Pharmacokinetic variables of palifermin have been determined in healthy volunteers and in metastatic colorectal cancer patients ([@b49]). Palifermin has been tested in clinical trials. In a phase I trial, Meropol determined that KGF was well tolerated at doses up to 40 μg/kg/day administered IV for 3 days before 5-FU plus leucovorin in patients with advanced colon cancers ([@b48]). This phase I study was randomized and suggested that patients treated with palifermin had a lower rate of grade 2 to 4 mucositis compared with patients who received placebo. It has been shown recently in a large randomized trial that palifermin reduced the incidence of grade 3 to 4 mucositis, decreased the median duration of mucositis, the duration of opioid analgesic use, and the incidence of use of parenteral nutrition in patients with hematologic cancers receiving total-body irradiation and HDC ([@b73]). Adverse events encountered were mild to moderate and transient and consisted mainly of rash, pruritus, erythema, edema, hypoesthesia, paresthesia, and mouth and tongue disorders like thickening and taste ([@b48]). Asymptomatic and reversible increases of amylases and lipases have also been observed ([@b66]).

In December 2004, palifermin was approved by the FDA for prevention of mucositis in patients receiving HDC and HSCT ([@b65]). This molecule is the first innovative "target-based" biologic agent for prevention of oral mucositis. Many trials are currently ongoing to determine the efficacy of this molecule in patients receiving radiotherapy, various chemotherapy regimens, or an allogenic transplant. In animal models, however, it has been shown that KGF can reduce acute oral and intestinal mucositis after chemoradiotherapy or fractionated irradiation ([@b22]; [@b19]). Recently in allogeneic and haploidentical bone marrow transplant animal models, KGF has shown interesting properties in reducing the incidence of graft-versus-host disease (GvHD). This effect seemed to be independent of repair of conditioning-induced injuries ([@b52]); [@b76]). In addition, it has been demonstrated that KGF has a favorable effect on lung repair in mice after allogeneic bone marrow transplant ([@b53]). A recent clinical study reported 69 patients who received palifermin after high-dose chemo-radiotherapy and allogeneic bone marrow transplantation. This medication was shown to be safe and well tolerated and did not have any negative effects on engraftment, GvHD, and survival ([@b9]). Another clinical study even suggested a survival benefit in patients with a high risk for acute GvHD when palifermin was added to tacrolimus and methotrexate ([@b61]).

Palliative cares
================

Palliative cares are implemented when mucositis is present. Continuation of routine oral care should be advised ([@b81]). In addition, dietary guidelines should be respected with avoidance of tobacco, alcohol, and spicy food. In some cases, parenteral or enteral supports may even be required. Finally, correct analgesia should be implemented. Morphine has been recommended as the treatment of choice for patients with mucositis undergoing HDC and HSCT ([@b63]). Prevailing clinical guidelines can help the clinician to choose to best analgesia for the patient ([@b80]). These guidelines include the use of opioids, nonopioids, adjuvant medications, and assessment tools. Topical anesthetics such as viscous lidocaine are frequently used to decrease pain related to oral mucositis; however, there are no experimental studies to support this approach. In addition, viscous lidocaine requires frequent applications and can be accompanied by burning sensation and the blunting of taste ([@b65]). A summary of available therapeutic and prophylactic interventions is presented in [Table 2](#tbl2){ref-type="table"}.

###### 

Candidate interventions for the management of oral mucositis

  General oral care                           Prevention                Palliative cares
  ------------------------------------------- ------------------------- ---------------------------------------------------------------
  Comprehensive patient education             Cryotherapy               Continuation of routine oral cares
  Standard oral care protocol                 Low-level laser therapy   Dietary guidelines: avoidance of alcohol, tobacco, spicy food
  Brushing teeth twice daily                  Amifostine                Enteral or parenteral support
  Daily flossing                              Gelclair^®^               Correct analgesia
  Mouth rinsing with sterile water            Benzydamine               
  Avoidance of spicy food, alcohol, tobacco   AES-14                    
                                              Palifermin                

Conclusions
===========

Oral mucositis is a frequent complication of anticancer treatments that has long been overlooked and underreported. The discrepancies between the different scales used to assess the severity of mucositis add more confusion, and large randomized clinical studies are scarce. Recently there has been greater focus on the frequency, physiopathology, consequences, and treatments of oral mucositis. These treatments remain largely based on anecdotal reports and assumptions, but some interesting studies have been done to provide evidence for these approaches. The understanding of the physiopathological basis of mucositis led to the development of target drug therapies, of which palifermin is the hallmark. This new drug constitutes a milestone in the management of cancer treatment-induced toxicity. Other molecules are currently under investigation, including transforming growth factor-β3, IL-11, and FGF-20 ([@b55]).

The physiopathology of mucositis can also explain why some preventive treatments like topical anti-infective agents may have some paradoxical effects. Guidelines have recently been developed to help clinicians in the daily management of this devastating toxicity ([@b63]; [@b68]). One can not insist enough on the importance of prevention, systematic oral care, and good patient information. When oral mucositis is profuse, appropriate analgesia is required. It is clear that treatment of mucositis is not based on a unique and non-existent magic drug, but rather on a logical and rational use of different modalities. Combining drugs in specific sequences and at different times relative to the administration of anticancer treatment will probably be the solution for adequate management of oral mucositis. In the near future, dose, timing, and sequencing of anti-mucositis agents will probably be as well developed as chemotherapy regimens ([@b55]). It is interesting to note that new drugs in development seem to have different mechanisms of action. In addition, it is no longer pure optimism to expect effective specific treatments of mucositis in the near future ([@b69]).
